{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:43:59Z","timestamp":1788536639244,"version":"build-2803163510"},"reference-count":41,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pirtobrutinib, a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi), demonstrated clinically meaningful antitumor responses in covalent BTKi pretreated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the global phase 1\/2 BRUIN study. In this multi\u2010center, open\u2010label, phase 2 trial, we investigated the efficacy and safety of pirtobrutinib in Chinese patients with BTKi pretreated relapsed\/refractory (R\/R) MCL, CLL\/SLL, or other B\u2010cell malignancies. All patients received pirtobrutinib once daily in continuous 28\u2010day cycles. The primary endpoint was the overall response rate (ORR). Efficacy was assessed in patients with MCL and CLL\/SLL with prior BTKi treatment and safety in all enrolled patients who received at least one dose of pirtobrutinib. Among 35 patients with covalent BTKis (cBTKi) pretreated MCL, the ORR was 62.9% (95% CI: 44.9, 78.5), the median duration of response (DOR) was not reached, and the 12\u2010month DOR rate was 59.7% (95% CI: 35.3, 77.5). Among 11 patients with cBTKi pretreated CLL\/SLL, the ORR was 63.6% (95% CI: 30.8, 89.1), and the 12\u2010month DOR rate was 83.3% (95% CI: 27.3, 97.5). The most common adverse events in the safety population (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200987) were anemia (32.2%) and neutrophil count decreased (31.0%). Grade\u2009\u22653 hemorrhage occurred in 2.3% of patients and there were no cases of atrial fibrillation\/flutter. Pirtobrutinib demonstrated clinically meaningful efficacy in Chinese patients with cBTKi pretreated R\/R MCL, preliminary antitumor activity in Chinese patients with cBTKi pretreated R\/R CLL\/SLL and was generally well\u2010tolerated with no new safety signals observed.\n                  <\/jats:p>","DOI":"10.1002\/ijc.35339","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T01:25:01Z","timestamp":1741742701000},"page":"2158-2168","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pirtobrutinib in Chinese patients with relapsed or refractory B\u2010cell malignancies: A single\u2010arm, open\u2010label, phase 2, multicenter trial"],"prefix":"10.1002","volume":"156","author":[{"given":"Yanyan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningjing","family":"Lin","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma Peking University Cancer Hospital &amp; Institute (Beijing Cancer Hospital)  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Tianjin China"},{"name":"Tianjin Institute of Health Science  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Department of Medical Oncology Sun Yat\u2010sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai East Hospital Tongji University School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Harbin Medical University Cancer Hospital  Harbin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Institute of Basic Medicine and Cancer (IBMC) The Cancer Hospital of the University of the Chinese Academy of Sciences (Zhejiang Cancer Hospital), Chinese Academy of Sciences  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7141-9236","authenticated-orcid":false,"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/ State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology Nanfang Hospital of Southern Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijiao","family":"Qian","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-5554","authenticated-orcid":false,"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma Peking University Cancer Hospital &amp; Institute (Beijing Cancer Hospital)  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma Peking University Cancer Hospital &amp; Institute (Beijing Cancer Hospital)  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26523"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00855-9"},{"key":"e_1_2_12_4_1","volume-title":"GLOBOCAN 2022. Population Fact Sheets","author":"World Health Organization","year":"2022"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.840616"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001811"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70335-3"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12030376"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30212-1"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201817"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.12703\/r\/10-22"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S265284"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092596"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114110"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051504"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013326"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143648"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0976"},{"key":"e_1_2_12_19_1","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez EB","year":"2023","journal-title":"Blood"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.081"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00562"},{"key":"e_1_2_12_24_1","volume-title":"Jaypirca (Pirtobrutinib): US prescribing information","author":"US Food and Drug Administration","year":"2023"},{"key":"e_1_2_12_25_1","volume-title":"Jaypirca (Pirtobrutinib): EU prescribing information","author":"European Medicines Agency","year":"2023"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.3748"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2009.10.012"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13456"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-716977"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231216886"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18519"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178430"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01755-5"},{"key":"e_1_2_12_40_1","unstructured":"Pharmacyclics LLC Janssen Biotech Inc.IMBRUVICA\u00ae (Ibrutinib): US prescribing information.\u00a02023.https:\/\/www.imbruvica.com\/. Accessed 13 Jun 2024."},{"key":"e_1_2_12_41_1","unstructured":"AstraZeneca.CALQUENCE\u00ae (Acalabrutinib): US prescribing information.2017.https:\/\/www.calquence.com\/. Accessed 13 Jun 2024."},{"key":"e_1_2_12_42_1","unstructured":"BeiGene.BRUKINSA\u00ae (Zanubrutinib): US prescribing information.2019.https:\/\/www.brukinsa.com\/. Accessed 13 Jun 2024."}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.35339","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.35339","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.35339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:01:34Z","timestamp":1787760094000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.35339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6,1]]}},"alternative-id":["10.1002\/ijc.35339"],"URL":"https:\/\/doi.org\/10.1002\/ijc.35339","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"2024-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}